Global Hemophilia Treatment

Hemophilia Treatment Comprehensive Study by Type (Replacement therapy, ITI therapy, Gene therapy), Disease Type (Hemophilia A, Hemophilia B, Hemophilia C), Treatment (Recombinant Coagulation Factor, Plasma-Derived Coagulation Factor, Desmopressin, Antifibrinolytic Agents), End-users (Hospitals, Clinics, Others) Players and Region - Global Market Outlook to 2030

Hemophilia Treatment Market by XX Submarkets | Forecast Years 2024-2030 | CAGR: 6.3%  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Hemophilia Treatment
Hemophilia is a rare condition in which the blood does not clot properly because it lacks sufficient blood-clotting proteins. It results into bleed severely from even a slight injury. This condition is typically caused by a hereditary lack of a coagulation factor. The hemophilia treatment involves receiving replacement of the specific clotting factor. Replacement therapy involves giving or replacing the clotting factors that are too low or missing in a patient.

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)
CAGR6.3%


The companies are exploring the market by adopting expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions across the globe to gain competitive advantage through combined collaborations. Analyst at AMA Research estimates that United States Players will contribute the maximum growth to Global Hemophilia Treatment market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Baxter International, Inc. (United States), Grifols SA (Spain), CSL Ltd. (Australia), Octapharma AG (Switzerland), Novo Nordisk (Denmark), Kedrion (Italy), Pfizer, Inc. (United States), Bayer AG (Germany), Biogen Idec, Inc. (United States) and Hospira, Inc. (United States) are some of the key players that are part of study coverage.

Segmentation Overview
AMA Research has segmented the market of Global Hemophilia Treatment market by Type (Replacement therapy, ITI therapy and Gene therapy) and Region.



On the basis of geography, the market of Hemophilia Treatment has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Disease Type, the sub-segment i.e. Hemophilia A will boost the Hemophilia Treatment market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Treatment, the sub-segment i.e. Recombinant Coagulation Factor will boost the Hemophilia Treatment market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by End-users, the sub-segment i.e. Hospitals will boost the Hemophilia Treatment market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Growing Awareness among People about Hemophilia Treatment and Increased Research and Development Activities

Market Growth Drivers:
Increased Prevalence of Hemophilia in Men, Increased Diagnostic Centres and Hospitals and Huge Investments by Major Players

Challenges:
High Cost Associated with Hemophilia Treatment

Restraints:
Side Effects of the Hemophilia Treatment

Opportunities:
Growing Healthcare Industry Worldwide and Robust Increase in the Distribution Channels

Market Leaders and their expansionary development strategies
In June 2020, Global biotherapeutics acquired exclusive global license rights to commercialize an adeno-associated virus (AAV) gene therapy program, AMT-061 for the treatment of hemophilia B from uniQure a leading gene therapy company. The AMT-061 program, currently in Phase 3 clinical trials, could be one of the first gene therapies to provide potentially long-term benefits to patients with hemophilia B.
in May 2022, Takeda Pharma has expanded its innovative rare diseases portfolio in India with the launch of Adynovate, an innovative extended half-life recombinant Factor VII (rFVIII) treatment, using established technology (controlled PEGylation), for haemophilia A


Key Target Audience
Hemophilia Treatment Providers, Distributors, Emerging Companies, Research Professionals and End-users

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Type
  • Replacement therapy
  • ITI therapy
  • Gene therapy
By Disease Type
  • Hemophilia A
  • Hemophilia B
  • Hemophilia C

By Treatment
  • Recombinant Coagulation Factor
  • Plasma-Derived Coagulation Factor
  • Desmopressin
  • Antifibrinolytic Agents

By End-users
  • Hospitals
  • Clinics
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increased Prevalence of Hemophilia in Men
      • 3.2.2. Increased Diagnostic Centres and Hospitals
      • 3.2.3. Huge Investments by Major Players
    • 3.3. Market Challenges
      • 3.3.1. High Cost Associated with Hemophilia Treatment
    • 3.4. Market Trends
      • 3.4.1. Growing Awareness among People about Hemophilia Treatment
      • 3.4.2. Increased Research and Development Activities
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Hemophilia Treatment, by Type, Disease Type, Treatment, End-users and Region (value) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Hemophilia Treatment (Value)
      • 5.2.1. Global Hemophilia Treatment by: Type (Value)
        • 5.2.1.1. Replacement therapy
        • 5.2.1.2. ITI therapy
        • 5.2.1.3. Gene therapy
      • 5.2.2. Global Hemophilia Treatment by: Disease Type (Value)
        • 5.2.2.1. Hemophilia A
        • 5.2.2.2. Hemophilia B
        • 5.2.2.3. Hemophilia C
      • 5.2.3. Global Hemophilia Treatment by: Treatment (Value)
        • 5.2.3.1. Recombinant Coagulation Factor
        • 5.2.3.2. Plasma-Derived Coagulation Factor
        • 5.2.3.3. Desmopressin
        • 5.2.3.4. Antifibrinolytic Agents
      • 5.2.4. Global Hemophilia Treatment by: End-users (Value)
        • 5.2.4.1. Hospitals
        • 5.2.4.2. Clinics
        • 5.2.4.3. Others
      • 5.2.5. Global Hemophilia Treatment Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
  • 6. Hemophilia Treatment: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Baxter International, Inc. (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Grifols SA (Spain)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. CSL Ltd. (Australia)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Octapharma AG (Switzerland)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Novo Nordisk (Denmark)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Kedrion (Italy)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Pfizer, Inc. (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Bayer AG (Germany)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Biogen Idec, Inc. (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Hospira, Inc. (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Hemophilia Treatment Sale, by Type, Disease Type, Treatment, End-users and Region (value) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Hemophilia Treatment (Value)
      • 7.2.1. Global Hemophilia Treatment by: Type (Value)
        • 7.2.1.1. Replacement therapy
        • 7.2.1.2. ITI therapy
        • 7.2.1.3. Gene therapy
      • 7.2.2. Global Hemophilia Treatment by: Disease Type (Value)
        • 7.2.2.1. Hemophilia A
        • 7.2.2.2. Hemophilia B
        • 7.2.2.3. Hemophilia C
      • 7.2.3. Global Hemophilia Treatment by: Treatment (Value)
        • 7.2.3.1. Recombinant Coagulation Factor
        • 7.2.3.2. Plasma-Derived Coagulation Factor
        • 7.2.3.3. Desmopressin
        • 7.2.3.4. Antifibrinolytic Agents
      • 7.2.4. Global Hemophilia Treatment by: End-users (Value)
        • 7.2.4.1. Hospitals
        • 7.2.4.2. Clinics
        • 7.2.4.3. Others
      • 7.2.5. Global Hemophilia Treatment Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Hemophilia Treatment: by Type(USD Million)
  • Table 2. Hemophilia Treatment Replacement therapy , by Region USD Million (2018-2023)
  • Table 3. Hemophilia Treatment ITI therapy , by Region USD Million (2018-2023)
  • Table 4. Hemophilia Treatment Gene therapy , by Region USD Million (2018-2023)
  • Table 5. Hemophilia Treatment: by Disease Type(USD Million)
  • Table 6. Hemophilia Treatment Hemophilia A , by Region USD Million (2018-2023)
  • Table 7. Hemophilia Treatment Hemophilia B , by Region USD Million (2018-2023)
  • Table 8. Hemophilia Treatment Hemophilia C , by Region USD Million (2018-2023)
  • Table 9. Hemophilia Treatment: by Treatment(USD Million)
  • Table 10. Hemophilia Treatment Recombinant Coagulation Factor , by Region USD Million (2018-2023)
  • Table 11. Hemophilia Treatment Plasma-Derived Coagulation Factor , by Region USD Million (2018-2023)
  • Table 12. Hemophilia Treatment Desmopressin , by Region USD Million (2018-2023)
  • Table 13. Hemophilia Treatment Antifibrinolytic Agents , by Region USD Million (2018-2023)
  • Table 14. Hemophilia Treatment: by End-users(USD Million)
  • Table 15. Hemophilia Treatment Hospitals , by Region USD Million (2018-2023)
  • Table 16. Hemophilia Treatment Clinics , by Region USD Million (2018-2023)
  • Table 17. Hemophilia Treatment Others , by Region USD Million (2018-2023)
  • Table 18. South America Hemophilia Treatment, by Country USD Million (2018-2023)
  • Table 19. South America Hemophilia Treatment, by Type USD Million (2018-2023)
  • Table 20. South America Hemophilia Treatment, by Disease Type USD Million (2018-2023)
  • Table 21. South America Hemophilia Treatment, by Treatment USD Million (2018-2023)
  • Table 22. South America Hemophilia Treatment, by End-users USD Million (2018-2023)
  • Table 23. Brazil Hemophilia Treatment, by Type USD Million (2018-2023)
  • Table 24. Brazil Hemophilia Treatment, by Disease Type USD Million (2018-2023)
  • Table 25. Brazil Hemophilia Treatment, by Treatment USD Million (2018-2023)
  • Table 26. Brazil Hemophilia Treatment, by End-users USD Million (2018-2023)
  • Table 27. Argentina Hemophilia Treatment, by Type USD Million (2018-2023)
  • Table 28. Argentina Hemophilia Treatment, by Disease Type USD Million (2018-2023)
  • Table 29. Argentina Hemophilia Treatment, by Treatment USD Million (2018-2023)
  • Table 30. Argentina Hemophilia Treatment, by End-users USD Million (2018-2023)
  • Table 31. Rest of South America Hemophilia Treatment, by Type USD Million (2018-2023)
  • Table 32. Rest of South America Hemophilia Treatment, by Disease Type USD Million (2018-2023)
  • Table 33. Rest of South America Hemophilia Treatment, by Treatment USD Million (2018-2023)
  • Table 34. Rest of South America Hemophilia Treatment, by End-users USD Million (2018-2023)
  • Table 35. Asia Pacific Hemophilia Treatment, by Country USD Million (2018-2023)
  • Table 36. Asia Pacific Hemophilia Treatment, by Type USD Million (2018-2023)
  • Table 37. Asia Pacific Hemophilia Treatment, by Disease Type USD Million (2018-2023)
  • Table 38. Asia Pacific Hemophilia Treatment, by Treatment USD Million (2018-2023)
  • Table 39. Asia Pacific Hemophilia Treatment, by End-users USD Million (2018-2023)
  • Table 40. China Hemophilia Treatment, by Type USD Million (2018-2023)
  • Table 41. China Hemophilia Treatment, by Disease Type USD Million (2018-2023)
  • Table 42. China Hemophilia Treatment, by Treatment USD Million (2018-2023)
  • Table 43. China Hemophilia Treatment, by End-users USD Million (2018-2023)
  • Table 44. Japan Hemophilia Treatment, by Type USD Million (2018-2023)
  • Table 45. Japan Hemophilia Treatment, by Disease Type USD Million (2018-2023)
  • Table 46. Japan Hemophilia Treatment, by Treatment USD Million (2018-2023)
  • Table 47. Japan Hemophilia Treatment, by End-users USD Million (2018-2023)
  • Table 48. India Hemophilia Treatment, by Type USD Million (2018-2023)
  • Table 49. India Hemophilia Treatment, by Disease Type USD Million (2018-2023)
  • Table 50. India Hemophilia Treatment, by Treatment USD Million (2018-2023)
  • Table 51. India Hemophilia Treatment, by End-users USD Million (2018-2023)
  • Table 52. South Korea Hemophilia Treatment, by Type USD Million (2018-2023)
  • Table 53. South Korea Hemophilia Treatment, by Disease Type USD Million (2018-2023)
  • Table 54. South Korea Hemophilia Treatment, by Treatment USD Million (2018-2023)
  • Table 55. South Korea Hemophilia Treatment, by End-users USD Million (2018-2023)
  • Table 56. Taiwan Hemophilia Treatment, by Type USD Million (2018-2023)
  • Table 57. Taiwan Hemophilia Treatment, by Disease Type USD Million (2018-2023)
  • Table 58. Taiwan Hemophilia Treatment, by Treatment USD Million (2018-2023)
  • Table 59. Taiwan Hemophilia Treatment, by End-users USD Million (2018-2023)
  • Table 60. Australia Hemophilia Treatment, by Type USD Million (2018-2023)
  • Table 61. Australia Hemophilia Treatment, by Disease Type USD Million (2018-2023)
  • Table 62. Australia Hemophilia Treatment, by Treatment USD Million (2018-2023)
  • Table 63. Australia Hemophilia Treatment, by End-users USD Million (2018-2023)
  • Table 64. Rest of Asia-Pacific Hemophilia Treatment, by Type USD Million (2018-2023)
  • Table 65. Rest of Asia-Pacific Hemophilia Treatment, by Disease Type USD Million (2018-2023)
  • Table 66. Rest of Asia-Pacific Hemophilia Treatment, by Treatment USD Million (2018-2023)
  • Table 67. Rest of Asia-Pacific Hemophilia Treatment, by End-users USD Million (2018-2023)
  • Table 68. Europe Hemophilia Treatment, by Country USD Million (2018-2023)
  • Table 69. Europe Hemophilia Treatment, by Type USD Million (2018-2023)
  • Table 70. Europe Hemophilia Treatment, by Disease Type USD Million (2018-2023)
  • Table 71. Europe Hemophilia Treatment, by Treatment USD Million (2018-2023)
  • Table 72. Europe Hemophilia Treatment, by End-users USD Million (2018-2023)
  • Table 73. Germany Hemophilia Treatment, by Type USD Million (2018-2023)
  • Table 74. Germany Hemophilia Treatment, by Disease Type USD Million (2018-2023)
  • Table 75. Germany Hemophilia Treatment, by Treatment USD Million (2018-2023)
  • Table 76. Germany Hemophilia Treatment, by End-users USD Million (2018-2023)
  • Table 77. France Hemophilia Treatment, by Type USD Million (2018-2023)
  • Table 78. France Hemophilia Treatment, by Disease Type USD Million (2018-2023)
  • Table 79. France Hemophilia Treatment, by Treatment USD Million (2018-2023)
  • Table 80. France Hemophilia Treatment, by End-users USD Million (2018-2023)
  • Table 81. Italy Hemophilia Treatment, by Type USD Million (2018-2023)
  • Table 82. Italy Hemophilia Treatment, by Disease Type USD Million (2018-2023)
  • Table 83. Italy Hemophilia Treatment, by Treatment USD Million (2018-2023)
  • Table 84. Italy Hemophilia Treatment, by End-users USD Million (2018-2023)
  • Table 85. United Kingdom Hemophilia Treatment, by Type USD Million (2018-2023)
  • Table 86. United Kingdom Hemophilia Treatment, by Disease Type USD Million (2018-2023)
  • Table 87. United Kingdom Hemophilia Treatment, by Treatment USD Million (2018-2023)
  • Table 88. United Kingdom Hemophilia Treatment, by End-users USD Million (2018-2023)
  • Table 89. Netherlands Hemophilia Treatment, by Type USD Million (2018-2023)
  • Table 90. Netherlands Hemophilia Treatment, by Disease Type USD Million (2018-2023)
  • Table 91. Netherlands Hemophilia Treatment, by Treatment USD Million (2018-2023)
  • Table 92. Netherlands Hemophilia Treatment, by End-users USD Million (2018-2023)
  • Table 93. Rest of Europe Hemophilia Treatment, by Type USD Million (2018-2023)
  • Table 94. Rest of Europe Hemophilia Treatment, by Disease Type USD Million (2018-2023)
  • Table 95. Rest of Europe Hemophilia Treatment, by Treatment USD Million (2018-2023)
  • Table 96. Rest of Europe Hemophilia Treatment, by End-users USD Million (2018-2023)
  • Table 97. MEA Hemophilia Treatment, by Country USD Million (2018-2023)
  • Table 98. MEA Hemophilia Treatment, by Type USD Million (2018-2023)
  • Table 99. MEA Hemophilia Treatment, by Disease Type USD Million (2018-2023)
  • Table 100. MEA Hemophilia Treatment, by Treatment USD Million (2018-2023)
  • Table 101. MEA Hemophilia Treatment, by End-users USD Million (2018-2023)
  • Table 102. Middle East Hemophilia Treatment, by Type USD Million (2018-2023)
  • Table 103. Middle East Hemophilia Treatment, by Disease Type USD Million (2018-2023)
  • Table 104. Middle East Hemophilia Treatment, by Treatment USD Million (2018-2023)
  • Table 105. Middle East Hemophilia Treatment, by End-users USD Million (2018-2023)
  • Table 106. Africa Hemophilia Treatment, by Type USD Million (2018-2023)
  • Table 107. Africa Hemophilia Treatment, by Disease Type USD Million (2018-2023)
  • Table 108. Africa Hemophilia Treatment, by Treatment USD Million (2018-2023)
  • Table 109. Africa Hemophilia Treatment, by End-users USD Million (2018-2023)
  • Table 110. North America Hemophilia Treatment, by Country USD Million (2018-2023)
  • Table 111. North America Hemophilia Treatment, by Type USD Million (2018-2023)
  • Table 112. North America Hemophilia Treatment, by Disease Type USD Million (2018-2023)
  • Table 113. North America Hemophilia Treatment, by Treatment USD Million (2018-2023)
  • Table 114. North America Hemophilia Treatment, by End-users USD Million (2018-2023)
  • Table 115. United States Hemophilia Treatment, by Type USD Million (2018-2023)
  • Table 116. United States Hemophilia Treatment, by Disease Type USD Million (2018-2023)
  • Table 117. United States Hemophilia Treatment, by Treatment USD Million (2018-2023)
  • Table 118. United States Hemophilia Treatment, by End-users USD Million (2018-2023)
  • Table 119. Canada Hemophilia Treatment, by Type USD Million (2018-2023)
  • Table 120. Canada Hemophilia Treatment, by Disease Type USD Million (2018-2023)
  • Table 121. Canada Hemophilia Treatment, by Treatment USD Million (2018-2023)
  • Table 122. Canada Hemophilia Treatment, by End-users USD Million (2018-2023)
  • Table 123. Mexico Hemophilia Treatment, by Type USD Million (2018-2023)
  • Table 124. Mexico Hemophilia Treatment, by Disease Type USD Million (2018-2023)
  • Table 125. Mexico Hemophilia Treatment, by Treatment USD Million (2018-2023)
  • Table 126. Mexico Hemophilia Treatment, by End-users USD Million (2018-2023)
  • Table 127. Company Basic Information, Sales Area and Its Competitors
  • Table 128. Company Basic Information, Sales Area and Its Competitors
  • Table 129. Company Basic Information, Sales Area and Its Competitors
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Hemophilia Treatment: by Type(USD Million)
  • Table 138. Hemophilia Treatment Replacement therapy , by Region USD Million (2025-2030)
  • Table 139. Hemophilia Treatment ITI therapy , by Region USD Million (2025-2030)
  • Table 140. Hemophilia Treatment Gene therapy , by Region USD Million (2025-2030)
  • Table 141. Hemophilia Treatment: by Disease Type(USD Million)
  • Table 142. Hemophilia Treatment Hemophilia A , by Region USD Million (2025-2030)
  • Table 143. Hemophilia Treatment Hemophilia B , by Region USD Million (2025-2030)
  • Table 144. Hemophilia Treatment Hemophilia C , by Region USD Million (2025-2030)
  • Table 145. Hemophilia Treatment: by Treatment(USD Million)
  • Table 146. Hemophilia Treatment Recombinant Coagulation Factor , by Region USD Million (2025-2030)
  • Table 147. Hemophilia Treatment Plasma-Derived Coagulation Factor , by Region USD Million (2025-2030)
  • Table 148. Hemophilia Treatment Desmopressin , by Region USD Million (2025-2030)
  • Table 149. Hemophilia Treatment Antifibrinolytic Agents , by Region USD Million (2025-2030)
  • Table 150. Hemophilia Treatment: by End-users(USD Million)
  • Table 151. Hemophilia Treatment Hospitals , by Region USD Million (2025-2030)
  • Table 152. Hemophilia Treatment Clinics , by Region USD Million (2025-2030)
  • Table 153. Hemophilia Treatment Others , by Region USD Million (2025-2030)
  • Table 154. South America Hemophilia Treatment, by Country USD Million (2025-2030)
  • Table 155. South America Hemophilia Treatment, by Type USD Million (2025-2030)
  • Table 156. South America Hemophilia Treatment, by Disease Type USD Million (2025-2030)
  • Table 157. South America Hemophilia Treatment, by Treatment USD Million (2025-2030)
  • Table 158. South America Hemophilia Treatment, by End-users USD Million (2025-2030)
  • Table 159. Brazil Hemophilia Treatment, by Type USD Million (2025-2030)
  • Table 160. Brazil Hemophilia Treatment, by Disease Type USD Million (2025-2030)
  • Table 161. Brazil Hemophilia Treatment, by Treatment USD Million (2025-2030)
  • Table 162. Brazil Hemophilia Treatment, by End-users USD Million (2025-2030)
  • Table 163. Argentina Hemophilia Treatment, by Type USD Million (2025-2030)
  • Table 164. Argentina Hemophilia Treatment, by Disease Type USD Million (2025-2030)
  • Table 165. Argentina Hemophilia Treatment, by Treatment USD Million (2025-2030)
  • Table 166. Argentina Hemophilia Treatment, by End-users USD Million (2025-2030)
  • Table 167. Rest of South America Hemophilia Treatment, by Type USD Million (2025-2030)
  • Table 168. Rest of South America Hemophilia Treatment, by Disease Type USD Million (2025-2030)
  • Table 169. Rest of South America Hemophilia Treatment, by Treatment USD Million (2025-2030)
  • Table 170. Rest of South America Hemophilia Treatment, by End-users USD Million (2025-2030)
  • Table 171. Asia Pacific Hemophilia Treatment, by Country USD Million (2025-2030)
  • Table 172. Asia Pacific Hemophilia Treatment, by Type USD Million (2025-2030)
  • Table 173. Asia Pacific Hemophilia Treatment, by Disease Type USD Million (2025-2030)
  • Table 174. Asia Pacific Hemophilia Treatment, by Treatment USD Million (2025-2030)
  • Table 175. Asia Pacific Hemophilia Treatment, by End-users USD Million (2025-2030)
  • Table 176. China Hemophilia Treatment, by Type USD Million (2025-2030)
  • Table 177. China Hemophilia Treatment, by Disease Type USD Million (2025-2030)
  • Table 178. China Hemophilia Treatment, by Treatment USD Million (2025-2030)
  • Table 179. China Hemophilia Treatment, by End-users USD Million (2025-2030)
  • Table 180. Japan Hemophilia Treatment, by Type USD Million (2025-2030)
  • Table 181. Japan Hemophilia Treatment, by Disease Type USD Million (2025-2030)
  • Table 182. Japan Hemophilia Treatment, by Treatment USD Million (2025-2030)
  • Table 183. Japan Hemophilia Treatment, by End-users USD Million (2025-2030)
  • Table 184. India Hemophilia Treatment, by Type USD Million (2025-2030)
  • Table 185. India Hemophilia Treatment, by Disease Type USD Million (2025-2030)
  • Table 186. India Hemophilia Treatment, by Treatment USD Million (2025-2030)
  • Table 187. India Hemophilia Treatment, by End-users USD Million (2025-2030)
  • Table 188. South Korea Hemophilia Treatment, by Type USD Million (2025-2030)
  • Table 189. South Korea Hemophilia Treatment, by Disease Type USD Million (2025-2030)
  • Table 190. South Korea Hemophilia Treatment, by Treatment USD Million (2025-2030)
  • Table 191. South Korea Hemophilia Treatment, by End-users USD Million (2025-2030)
  • Table 192. Taiwan Hemophilia Treatment, by Type USD Million (2025-2030)
  • Table 193. Taiwan Hemophilia Treatment, by Disease Type USD Million (2025-2030)
  • Table 194. Taiwan Hemophilia Treatment, by Treatment USD Million (2025-2030)
  • Table 195. Taiwan Hemophilia Treatment, by End-users USD Million (2025-2030)
  • Table 196. Australia Hemophilia Treatment, by Type USD Million (2025-2030)
  • Table 197. Australia Hemophilia Treatment, by Disease Type USD Million (2025-2030)
  • Table 198. Australia Hemophilia Treatment, by Treatment USD Million (2025-2030)
  • Table 199. Australia Hemophilia Treatment, by End-users USD Million (2025-2030)
  • Table 200. Rest of Asia-Pacific Hemophilia Treatment, by Type USD Million (2025-2030)
  • Table 201. Rest of Asia-Pacific Hemophilia Treatment, by Disease Type USD Million (2025-2030)
  • Table 202. Rest of Asia-Pacific Hemophilia Treatment, by Treatment USD Million (2025-2030)
  • Table 203. Rest of Asia-Pacific Hemophilia Treatment, by End-users USD Million (2025-2030)
  • Table 204. Europe Hemophilia Treatment, by Country USD Million (2025-2030)
  • Table 205. Europe Hemophilia Treatment, by Type USD Million (2025-2030)
  • Table 206. Europe Hemophilia Treatment, by Disease Type USD Million (2025-2030)
  • Table 207. Europe Hemophilia Treatment, by Treatment USD Million (2025-2030)
  • Table 208. Europe Hemophilia Treatment, by End-users USD Million (2025-2030)
  • Table 209. Germany Hemophilia Treatment, by Type USD Million (2025-2030)
  • Table 210. Germany Hemophilia Treatment, by Disease Type USD Million (2025-2030)
  • Table 211. Germany Hemophilia Treatment, by Treatment USD Million (2025-2030)
  • Table 212. Germany Hemophilia Treatment, by End-users USD Million (2025-2030)
  • Table 213. France Hemophilia Treatment, by Type USD Million (2025-2030)
  • Table 214. France Hemophilia Treatment, by Disease Type USD Million (2025-2030)
  • Table 215. France Hemophilia Treatment, by Treatment USD Million (2025-2030)
  • Table 216. France Hemophilia Treatment, by End-users USD Million (2025-2030)
  • Table 217. Italy Hemophilia Treatment, by Type USD Million (2025-2030)
  • Table 218. Italy Hemophilia Treatment, by Disease Type USD Million (2025-2030)
  • Table 219. Italy Hemophilia Treatment, by Treatment USD Million (2025-2030)
  • Table 220. Italy Hemophilia Treatment, by End-users USD Million (2025-2030)
  • Table 221. United Kingdom Hemophilia Treatment, by Type USD Million (2025-2030)
  • Table 222. United Kingdom Hemophilia Treatment, by Disease Type USD Million (2025-2030)
  • Table 223. United Kingdom Hemophilia Treatment, by Treatment USD Million (2025-2030)
  • Table 224. United Kingdom Hemophilia Treatment, by End-users USD Million (2025-2030)
  • Table 225. Netherlands Hemophilia Treatment, by Type USD Million (2025-2030)
  • Table 226. Netherlands Hemophilia Treatment, by Disease Type USD Million (2025-2030)
  • Table 227. Netherlands Hemophilia Treatment, by Treatment USD Million (2025-2030)
  • Table 228. Netherlands Hemophilia Treatment, by End-users USD Million (2025-2030)
  • Table 229. Rest of Europe Hemophilia Treatment, by Type USD Million (2025-2030)
  • Table 230. Rest of Europe Hemophilia Treatment, by Disease Type USD Million (2025-2030)
  • Table 231. Rest of Europe Hemophilia Treatment, by Treatment USD Million (2025-2030)
  • Table 232. Rest of Europe Hemophilia Treatment, by End-users USD Million (2025-2030)
  • Table 233. MEA Hemophilia Treatment, by Country USD Million (2025-2030)
  • Table 234. MEA Hemophilia Treatment, by Type USD Million (2025-2030)
  • Table 235. MEA Hemophilia Treatment, by Disease Type USD Million (2025-2030)
  • Table 236. MEA Hemophilia Treatment, by Treatment USD Million (2025-2030)
  • Table 237. MEA Hemophilia Treatment, by End-users USD Million (2025-2030)
  • Table 238. Middle East Hemophilia Treatment, by Type USD Million (2025-2030)
  • Table 239. Middle East Hemophilia Treatment, by Disease Type USD Million (2025-2030)
  • Table 240. Middle East Hemophilia Treatment, by Treatment USD Million (2025-2030)
  • Table 241. Middle East Hemophilia Treatment, by End-users USD Million (2025-2030)
  • Table 242. Africa Hemophilia Treatment, by Type USD Million (2025-2030)
  • Table 243. Africa Hemophilia Treatment, by Disease Type USD Million (2025-2030)
  • Table 244. Africa Hemophilia Treatment, by Treatment USD Million (2025-2030)
  • Table 245. Africa Hemophilia Treatment, by End-users USD Million (2025-2030)
  • Table 246. North America Hemophilia Treatment, by Country USD Million (2025-2030)
  • Table 247. North America Hemophilia Treatment, by Type USD Million (2025-2030)
  • Table 248. North America Hemophilia Treatment, by Disease Type USD Million (2025-2030)
  • Table 249. North America Hemophilia Treatment, by Treatment USD Million (2025-2030)
  • Table 250. North America Hemophilia Treatment, by End-users USD Million (2025-2030)
  • Table 251. United States Hemophilia Treatment, by Type USD Million (2025-2030)
  • Table 252. United States Hemophilia Treatment, by Disease Type USD Million (2025-2030)
  • Table 253. United States Hemophilia Treatment, by Treatment USD Million (2025-2030)
  • Table 254. United States Hemophilia Treatment, by End-users USD Million (2025-2030)
  • Table 255. Canada Hemophilia Treatment, by Type USD Million (2025-2030)
  • Table 256. Canada Hemophilia Treatment, by Disease Type USD Million (2025-2030)
  • Table 257. Canada Hemophilia Treatment, by Treatment USD Million (2025-2030)
  • Table 258. Canada Hemophilia Treatment, by End-users USD Million (2025-2030)
  • Table 259. Mexico Hemophilia Treatment, by Type USD Million (2025-2030)
  • Table 260. Mexico Hemophilia Treatment, by Disease Type USD Million (2025-2030)
  • Table 261. Mexico Hemophilia Treatment, by Treatment USD Million (2025-2030)
  • Table 262. Mexico Hemophilia Treatment, by End-users USD Million (2025-2030)
  • Table 263. Research Programs/Design for This Report
  • Table 264. Key Data Information from Secondary Sources
  • Table 265. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Hemophilia Treatment: by Type USD Million (2018-2023)
  • Figure 5. Global Hemophilia Treatment: by Disease Type USD Million (2018-2023)
  • Figure 6. Global Hemophilia Treatment: by Treatment USD Million (2018-2023)
  • Figure 7. Global Hemophilia Treatment: by End-users USD Million (2018-2023)
  • Figure 8. South America Hemophilia Treatment Share (%), by Country
  • Figure 9. Asia Pacific Hemophilia Treatment Share (%), by Country
  • Figure 10. Europe Hemophilia Treatment Share (%), by Country
  • Figure 11. MEA Hemophilia Treatment Share (%), by Country
  • Figure 12. North America Hemophilia Treatment Share (%), by Country
  • Figure 13. Global Hemophilia Treatment share by Players 2023 (%)
  • Figure 14. Global Hemophilia Treatment share by Players (Top 3) 2023(%)
  • Figure 15. Global Hemophilia Treatment share by Players (Top 5) 2023(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Baxter International, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 18. Baxter International, Inc. (United States) Revenue: by Geography 2023
  • Figure 19. Grifols SA (Spain) Revenue, Net Income and Gross profit
  • Figure 20. Grifols SA (Spain) Revenue: by Geography 2023
  • Figure 21. CSL Ltd. (Australia) Revenue, Net Income and Gross profit
  • Figure 22. CSL Ltd. (Australia) Revenue: by Geography 2023
  • Figure 23. Octapharma AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 24. Octapharma AG (Switzerland) Revenue: by Geography 2023
  • Figure 25. Novo Nordisk (Denmark) Revenue, Net Income and Gross profit
  • Figure 26. Novo Nordisk (Denmark) Revenue: by Geography 2023
  • Figure 27. Kedrion (Italy) Revenue, Net Income and Gross profit
  • Figure 28. Kedrion (Italy) Revenue: by Geography 2023
  • Figure 29. Pfizer, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 30. Pfizer, Inc. (United States) Revenue: by Geography 2023
  • Figure 31. Bayer AG (Germany) Revenue, Net Income and Gross profit
  • Figure 32. Bayer AG (Germany) Revenue: by Geography 2023
  • Figure 33. Biogen Idec, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 34. Biogen Idec, Inc. (United States) Revenue: by Geography 2023
  • Figure 35. Hospira, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 36. Hospira, Inc. (United States) Revenue: by Geography 2023
  • Figure 37. Global Hemophilia Treatment: by Type USD Million (2025-2030)
  • Figure 38. Global Hemophilia Treatment: by Disease Type USD Million (2025-2030)
  • Figure 39. Global Hemophilia Treatment: by Treatment USD Million (2025-2030)
  • Figure 40. Global Hemophilia Treatment: by End-users USD Million (2025-2030)
  • Figure 41. South America Hemophilia Treatment Share (%), by Country
  • Figure 42. Asia Pacific Hemophilia Treatment Share (%), by Country
  • Figure 43. Europe Hemophilia Treatment Share (%), by Country
  • Figure 44. MEA Hemophilia Treatment Share (%), by Country
  • Figure 45. North America Hemophilia Treatment Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Baxter International, Inc. (United States)
  • Grifols SA (Spain)
  • CSL Ltd. (Australia)
  • Octapharma AG (Switzerland)
  • Novo Nordisk (Denmark)
  • Kedrion (Italy)
  • Pfizer, Inc. (United States)
  • Bayer AG (Germany)
  • Biogen Idec, Inc. (United States)
  • Hospira, Inc. (United States)
Select User Access Type

Key Highlights of Report


Mar 2024 205 Pages 66 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Hemophilia Treatment Quantitative research analysis
Global Hemophilia Treatment Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Baxter International, Inc. (United States), Grifols SA (Spain), CSL Ltd. (Australia), Octapharma AG (Switzerland), Novo Nordisk (Denmark), Kedrion (Italy), Pfizer, Inc. (United States), Bayer AG (Germany), Biogen Idec, Inc. (United States) and Hospira, Inc. (United States) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Growing Awareness among People about Hemophilia Treatment " is seen as one of major influencing trends for Hemophilia Treatment Market during projected period 2023-2030.
The Hemophilia Treatment market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Hemophilia Treatment Report?

Have a Query? Click Here

Other Related Reports

Gastrointestinal Cancer Drugs Comprehensive Study by Application (Hospitals, Specialized Cancer Treatment Centers, Clinics, Ambulatory Surgical Centers), Drug Type (Ramucirumab, Docetaxel, Doxorubici...
$ 3750
Hormone Refractory Prostate Cancer Comprehensive Study by Treatment (Chemotherapy, Hormonal Therapy, Immunotherapy, Radiation Therapy, Surgery), End-users (Hospitals, Ambulatory Surgical Centers, Spe...
$ 3650
Metastatic Uveal Melanoma Thereapeutics Comprehensive Study by Type (Sunitinib Malate, Vincristine Sulfate Liposomal, LY-2801653, Sotrastaurin Acetate, Others), Application (Hospital, Clinic, Others)...
$ 3750
Brachytherapy Comprehensive Study by Type (High Dose Rate (HDR) Brachytherapy , Low Dose (LDR) Brachytherapy), Application (Prostate Cancer, Gynecological Cancer, Breast Cancer, Other Cancers), End U...
$ 3450
Q Fever Comprehensive Study by Type (Acute Q Fever, Chronic Q Fever), Treatment (Medicines (Doxycycline), Vaccination), End-users (Hospitals & Clinics, Diagnostic Centers, Surgical Centers), Diagnosi...
$ 3450
Mumps Virus Testing Comprehensive Study by Type (Cell Culture/Immunofluorescence, Semi-Quantitative Enzyme-Linked Immunosorbent Assay, Semi-Quantitative Chemiluminescent Immunoassay, Qualitative Real...
$ 3450